title: A 12-month treatment with tenofovir does not impair bone mineral accrual in HIV-infected children.
abstract: BACKGROUND
  Short-term use of tenofovir (TDF) has been associated with bone mineral loss in adults and children.
  
  
  OBJECTIVE
  To assess whether the substitution of stavudine with TDF would result in decreased bone mineral content (BMC) and bone mineral density (BMD) accrual in HIV-infected children.
  
  
  METHODS
  The lumbar spine and whole-body BMC and BMD were measured by dual-energy x-ray absorptiometry in 16 HIV-infected children (age range: 6.4-17.9 years) on stable highly active antiretroviral therapy. Bone measurements were obtained 12 months before the switch, at baseline, and 12 months after switching to TDF. Expected changes in bone measurements were calculated from cross-sectional data obtained from 166 healthy children.
  
  
  RESULTS
  The BMC and BMD increments observed before switching therapy did not differ from expected increments. Similarly, the changes detected during treatment with TDF did not differ significantly from those calculated in healthy controls.
  
  
  CONCLUSIONS
  Substitution to a TDF-containing antiretroviral regimen does not seem to impair bone mineral accrual in children showing a good immunologic response to antiretroviral treatment.
authors.affiliation: Department of Pediatrics, L. Sacco Hospital, University of Milan, Milan, Italy.
authors.forename: Vania
authors.initials: V
authors.lastname: Giacomet
authors.forename: Stefano
authors.initials: S
authors.lastname: Mora
authors.forename: Laura
authors.initials: L
authors.lastname: Martelli
authors.forename: Marzia
authors.initials: M
authors.lastname: Merlo
authors.forename: Mariateresa
authors.initials: M
authors.lastname: Sciannamblo
authors.forename: Alessandra
authors.initials: A
authors.lastname: Viganò
mesh_terms: D015502:Absorptiometry, Photon; D000225:Adenine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000293:Adolescent; D019380:Anti-HIV Agents / Q000008:administration & dosage* / Q000009:adverse effects*; D023241:Antiretroviral Therapy, Highly Active / Q000009:adverse effects; D015519:Bone Density / Q000187:drug effects*; D002648:Child; D015658:HIV Infections / Q000188:drug therapy*; D006801:Humans; D063065:Organophosphonates / Q000008:administration & dosage* / Q000009:adverse effects* / Q000627:therapeutic use; D018119:Stavudine / Q000008:administration & dosage / Q000009:adverse effects; D000068698:Tenofovir
chemical_list: D019380:Anti-HIV Agents; D063065:Organophosphonates; D000068698:Tenofovir; D018119:Stavudine; D000225:Adenine